PSORIASIS TREATMENT WITH BIOLOGICS: BEYOND TUMOR NECROSIS FACTOR α INIHIBITORS – THE PRESENT AND THE FUTURE
Abstract
Psoriasis is a chronic systemic T-cell-mediated inflammatory disease with high morbidity. Psoriasis’s investigation has been intense, improving knowledge on physiopathology and leading to new biologic therapies for moderate and severe psoriasis’s treatment. This review will focus the present and the future of anti-cytokine therapies, beside the class of tumor necrosis factor-α (TNF-α) blockers.
KEYWORDS – Antibodies, Monoclonal; Biological agents; Dermatologic agents; Psoriasis.
Downloads
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).